WHV’s single-site study WHV138, a double blind, randomized, placebo-controlled phase 1b trial was successfully completed after 3 years since study initiation. The database was recently locked and unblinded and the study participants are currently being informed of their treatment assignment. The polyvalent DNA/Protein HIV Vaccine candidate PDPHV was found to be safe and well-tolerated; no safety concerns were seen throughout the entire trial period. Immunogenicity analyses are ongoing and first results are similar to those of the HVTN124 trial, which have been published recently in The Lancet HIV.
